Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CisGem plus pembrolizumab in advanced or metastatic biliary tract cancer
2017-003323-30Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: PFS rate at 6 months. Status: unknown.
02
Drugs
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2017-003323-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003323-30.